The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Poster
First-in-human, open-label, phase 1 study of CD30-directed antibody drug conjugate, PF-08046044 (35C), in patients with relapsed/refractory lymphomas: dose escalation safety and preliminary efficacy
Christina Poh, Carlo Visco, Michael Spinner, Kendan Jones-Isaac, Mina Nayeri, Erika Rudnicki, Maria Delioukina, Swetha Thiruvengadam
CD30-directed Antibody-Glucuronide with TOP1 Inhibitor Payload | June 12, 2025
C5801001 | NCT06254495
Poster
Trial in Progress: Open-label Phase 1 Study to Evaluate Safety of SGN-35C in Adults With Select Relapsed/Refractory Lymphomas (SGN35C-001)
Kambhampati S, Herrera A, Spinner M, Poh C, Phillips E, Ribrag V, Yan M, Chen TL, Vose J
CD30-directed Antibody-Glucuronide with TOP1 Inhibitor Payload | December 10, 2024 | ASH 2024
C5801001 | NCT06254495